

A Specific, Sensitive and High-throughput Assay to Simultaneously Quantify Methylcobalamin, Cyanocobalamin and Cobamamide in Finished Goods using LC/MS/MS



Aihua Liu, Michael Landesman, Uri Hong, Daniel Taylor, Edgar Grigorian, Spencer Carter Genysis Labs, 391 S Orange Street Suite F, Salt Lake City, UT 84104

PURPOSE

Vitamin B12, including cyanocobalamin (cB12), methylcobalamin (mB12), adenosylcobalamin (cobamamide) and hydroxocobalamin, has a key role in the normal functioning of the brain and nervous system, and in the formation of red blood cells, Recently, mB12 is rapidly gaining popularity as the supplemental B12 form due to its higher bioavailability, longer retention time in tissue and it does not contain toxic cyanide. The Daily Value (%DV) of vitamin B12 has been revised from 6.0 µg downward to 2.4 µg as of May 2016, and its low content in supplements requires ultra-sensitive quantitation method. In this paper, we developed a specific, sensitive and highthroughput quantitative method for cB12, mB12 and cobamamide in finished goods using LC/MS/MS.

METHOD

Sample Preparation and Extraction:

About 2 g of sample was extracted with water and methanol. The extracted sample was cleaned by 0.20 µM filtration before analysis.

UPLC-MS Conditions

UPLC system: Nexera UPLC system including SIL-30AC auto-sampler, controller, column heater and binary pump (SHIMADZU) Column: 100x2.1 mm, 1.6 µm CORTECS C18 (Waters) Mobile Phase A: Formic Acid and water Mobile Phase B: Formic Acid and acetonitrile Flow rate: 0.40 mL/min Pump Gradient Cycle time: 6.0 minutes MS detector: Triple Quadrupole 4000 MS (AB Sciex) MS Parameters: see Table 1



Figure 1: Chemical Structure of Cobalamins

MS CONDITIONS								
Scan Mode	Ion Mode		5	Source Temperature (°C)			Dwell Time (ms)	
MRM	Positive			500		100		
Compounds Parameters								
Analyte	Q1	Q3		RT (min)	Typical	DP	Typical CE	
Cobamamide	791.4	665.7		1.92	52		32	
mB12	673.6	665.6		2.16	75		75	
cB12	678.6	358.9		1.80	75		71	

Table 1: MS Condition for Cobalamins



light protection, respectively.





Figure 3: Blank Sample Chromatogram Figure 4: LLOQ Standard Chromatogram

Compound	Cobabamide (Area)	cB12 (Area)	mB12 (Area)
Replicate 1	2643	3581	15510
Replicate 2	2491	3458	16740
Replicate 3	2487	3306	16860
Replicate 4	2445	3423	16210
Replicate 5	2709	3240	16370
Replicate 6	2475	3714	15410
Average	2542	3454	16183
Std Dev	107	175	609
RSD (%)	42	51	38

Table 2: System Suitability of Cobalamins

Analyte	Target (ng/mL)	Accuracy(%)	Regression
Cobamamide	1.84	88.9	
	3.68	97.3	Quadratic
	9.19	96.0	1/x Weighting
	46.0	103	r ² = 0.99986
	91.9	98.9	
	184	100	
	2.00	98.1	
	N/A	N/A	Quadratic
oP12	9.99	101	1/x Weighting
CB12	50.0	99.2	r ² = 0.99930
	100	104	
	200	98.2	
mB12	1.82	102	
	3.63	98.6	Quadratic
	9.09	97.2	1/x Weighting
	45.4	105	r ² = 0.99922
	90.9	96.8	
	182	100	

RESULTS and DISCUSSION

During method development, standard solution stability was evaluated, and the data indicated that B12 is very sensitive to light and temperature. In order to minimize the effect of the light and temperature, the sample is processed without light exposure at reduced temperature conditions (Fig. 2). Both protein and non-protein matrix samples were investigated, and it was found that the different diluents were necessary for different types of matrix. The method was successfully validated

over the range of 2.00-200 ng/mL in both protein and non-protein matrix with the target concentration of sample preparation at 100 ng/mL. The specificity experiment showed that there was no significant contribution between analytes/IS and no

before sample analysis, and RSD was <6% (Table 2). The response linearity study revealed that quadratic regression with 1/X weighing factor provides the best fit, and the correlation coefficient r² is ≥0.995 (Fig. 4 and Table 3). The accuracy experiment showed that the spiking recovery is within ±20% (Table 4). The %RSD of precision and repeatability was <3.6% (Table 4). The standard solution stability and extracted sample stability was established for up to 19 and 3 days at 1-8°C in

visible interference peaks showed in blank diluent at the expected retention time (Fig. 2). The LLOQ has sufficient sensitivity (S/N> 10) (Fig. 3). System suitability consisted of six replicate injections of the middle standard solution and was injected



Analyte		QC Levels			
		Low QC (10.0 ng/mL)	Medium QC (50.0 ng/mL)	High QC (150 ng/mL)	
Cobamamide	Replicate 1	96.5	92.5	98.9	
	Replicate 2	103	97.9	90.3	
	Replicate 3	96.7	97.4	97.9	
	Average	98.8	96.0	95.7	
cB12	Replicate 1	93.2	91.0	96.5	
	Replicate 2	89.2	98.3	97.4	
	Replicate 3	93.1	103	104	
	Average	91.8	97.4	99.4	
mB12	Replicate 1	92.6	92.2	93.6	
	Replicate 2	94.8	91.3	91.6	
	Replicate 3	93.9	89.5	85.5	
	Average	93.7	91	90.2	





1 A	4.			
Analyte		Accuracy High QC (150 ng/mL)		
		98.9		
	Accuracy (%)	90.3		
		97.9		
		99.0		
Cobamamide		98.5		
		94.6		
	Average	96.5		
	SD	3.5		
	RSD%	3.6		
		97.4		
	Accuracy (%)	104		
		96.4		
		97.1		
cB12		96.2		
		101		
	Average	98.8		
	SD	3.3		
	RSD%	3.4		
		91.6		
mB12		85.5		
	Accuracy (%)	91.8		
		90.9		
		92.3		
		87.0		
	Average	89.8		
	SD	2.8		
	RSD%	3.2		

Table 4: The Precision Data

Table 3: The Post Spiking Accuracy (%)

CONCLUSIONS

This is the first known published specific, fast and high-throughput LC/MS/MS assay for quantification of cB12, mB12 and cobamamide in finished goods.